Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy

Data from a real-world analysis of patients with DLBCL showed that 25.2% experienced relapsed/refractory disease after first-line therapy. One- and 3-year real-world OS from first-line treatment initiation were 88.5% and 78.4%, respectively. Patients who received later lines of therapy experienced lower 1- and 3-year real-world OS (from second-line initiation: 62.4% and 46.4%, respectively).